Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NivoMes trial (nivolumab): what clinicians have said so far
Nivolumab in Patients With Recurrent Malignant Mesothelioma
- NCT02497508 ↗
- Completed
- The Netherlands Cancer Institute
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NivoMes (nivolumab in recurrent malignant pleural mesothelioma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NivoMes so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 9 posts on X, typically up to 40 once built |
The trial
ClinicalTrials.gov- Official title
- A Single Arm Phase II Study of Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma: Interim Biopsy Analysis to Determine Efficacy. Acronym: NivoMes Study
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- nivolumab
- Arms
- Nivolumab · Experimental
- Enrollment
- 33
- Primary outcomes
- DCR
- Sponsor
- The Netherlands Cancer Institute with Bristol-Myers Squibb
- Start
- Jul 2015
- Primary completion
- Jul 2017
- Results posted
- No
- Registry record
- NCT02497508 · updated Sep 14, 2017
Publications
linked from the registry- Desai AP, Kosari F, Disselhorst M, Yin J, Agahi A, Peikert T, Udell J, Johnson SH, Smadbeck J, Murphy S, Karagouga G, McCune A, Schaefer-Klein J, Borad MJ, Cheville J, Vasmatzis G, Baas P, Mansfield A. Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy. J Immunother Cancer. 2023 Jun;11(6):e006035. doi: 10.1136/jitc-2022-006035. PubMed 37279993